Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446041 · ClinicalTrials.gov registry record
ICS/LABA Adherence and COPD Exacerbation
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 10,000
- Enrollment target
NCT02446041 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 10,000 participants.
The verdict
NCT02446041 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 10,000 participants
- Enrollment target
Study Summary
The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446041
The ClinicalTrials.gov registry entry for NCT02446041 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT02446041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02446041 about?
NCT02446041 is a clinical study titled "ICS/LABA Adherence and COPD Exacerbation". The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adh...
What is the current status of trial NCT02446041?
This trial is currently completed. The enrollment target is 10,000 participants. The study started on 2015-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02446041?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT02446041?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.